Alaska Medicaid GLP-1 Coverage 2026: Pattern #49 — Categorical AOM Exclusion by Absence From the March 2026 PDL (Wegovy / Zepbound / Saxenda Listed in No Class) in a Medicaid-Expansion State With the Largest Geography in the US and a 100% FMAP Tribal Health Compact Overlay

TL;DR — what Alaska Medicaid covers and does not cover

The exclusion operates by absence rather than by an affirmative categorical sentence. The Alaska Medicaid Preferred Drug List effective March 1, 2026 (42 pages, posted January 23, 2026 by the Alaska Department of Health, Division of Health Care Services) lists the full HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS class on page 6 with PDL preferred “ON” status (effective November 1, 2025):

• OZEMPIC (semaglutide subcutaneous) — dosages 2 MG/3 ML, 0.25 / 0.5 MG/1.5 ML, 1 MG/3 ML, 2 MG/0.75 ML, and 4 MG/3 ML
• MOUNJARO (tirzepatide subcutaneous) — dosages 2.5 / 5 / 7.5 / 10 / 12.5 / 15 MG per 0.5 ML
• RYBELSUS (oral semaglutide tablets) — 3 MG, 7 MG, 14 MG
• TRULICITY (dulaglutide pen) — 0.75 / 1.5 / 3 / 4.5 MG per 0.5 ML
• VICTOZA (liraglutide)
• BYDUREON BCISE (exenatide extended-release)
• ADLYXIN (lixisenatide)

What Alaska Medicaid does NOT cover at the PDL level (the AOM exclusion by absence):

• Wegovy (semaglutide for chronic weight management) — not on the PDL in any class
• Zepbound (tirzepatide for chronic weight management) — not on the PDL in any class
• Saxenda (liraglutide for chronic weight management) — not on the PDL in any class

Alaska is NOT among the approximately 13 states KFF January 2026 identifies as covering GLP-1s for obesity under FFS Medicaid as of January 2026. The KFF verbatim federal framework:

“coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively.”

The federal-floor implications:

• T2D coverage is required — honored via PDL preferred “ON” status for the seven incretins listed above.
• Wegovy for cardiovascular event risk reduction (SELECT/MACE) is federally required since the March 2024 FDA label expansion. Wegovy is absent from the Alaska PDL — meaning the carve-out, if honored, would presumably route through the General PA Form non-preferred pathway. UNVERIFIED — no Alaska policy bulletin operationalizing this federal floor was located.
• Zepbound for moderate-to-severe obstructive sleep apnea (SURMOUNT-OSA) is federally required since the December 2024 FDA label expansion. Zepbound is absent from the Alaska PDL. UNVERIFIED.
• Wegovy for MASH (August 2025 FDA label expansion) — UNVERIFIED.
• Wegovy pediatric (ages 12+) — UNVERIFIED.

1. Federal authority for the Alaska AOM exclusion

The federal Medicaid drug rebate statute at 42 U.S.C. § 1396r-8(d)(2)(A) grants states an optional authority to exclude “agents when used for anorexia, weight loss, or weight gain” from Medicaid coverage. Alaska has exercised this authority not via an explicit categorical sentence in a state regulation or PDL document, but by absence — Wegovy, Zepbound, and Saxenda do not appear in any class of the Alaska Medicaid PDL effective March 1, 2026. The Alaska Medicaid “Prior Authorization Medication List” published at health.alaska.gov/en/education/prior-authorization-medication/ likewise does not list any GLP-1 by name — meaning no drug-specific PA pathway is established for the AOM molecules.

Unlike Montana Pattern #46 (which codifies the exclusion in the DPHHS Pharmacy Program “Not Covered” bucket verbatim) or Maine Pattern #39 (which anchors the exclusion in a freestanding state regulation at 10-144 C.M.R. ch. 101, Ch. II, § 80.06(A)) or Mississippi Pattern #35 (which executes a State Plan Amendment carve-back-in via SPA 23-0013), Alaska operates the exclusion at the PDL-absence level only. There is no Alaska Administrative Code rule specifically naming weight-loss drugs as a separate excluded class.

Pattern #49 is therefore a silent operational exclusion in the same architectural family as Florida (silent operational exclusion via AHCA PDL omission) and South Dakota Pattern #45 (functional AOM exclusion by absence; the OptumRx SD-specific GLP-1 PA form pre-codes ONLY T2D as the indication checkbox). What distinguishes Alaska from those peers: Alaska’s expansion-state status, its 100% FMAP Tribal Health Compact, its unique geographic scale, and its FFS-only single-PDL architecture.

2. The Alaska Medicaid Preferred Drug List effective March 1, 2026

The binding policy document is the Alaska Medicaid Preferred Drug List effective March 1, 2026 — a 42-page document posted January 23, 2026 by the Alaska Department of Health, Division of Health Care Services, accessible at health.alaska.gov/media/yaon3cxf/pdl-effective-date_20260301v11.pdf. An upcoming PDL effective June 1, 2026 is published at health.alaska.gov/media/dq0ohdan/pdl_effective-date_20260601.pdf. The PDL landing page is health.alaska.gov/en/education/pdl-preferred-drug-list/.

2.1 Page 6 — HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS class

The drug class is listed on page 6 of the March 1, 2026 PDL with seven drugs at PDL preferred “ON” status (effective November 1, 2025):

2.2 The AOM exclusion by absence

Wegovy (semaglutide injection for chronic weight management at the 2.4 MG maintenance dose), Zepbound (tirzepatide injection for chronic weight management at 5/10/15 MG doses), and Saxenda (liraglutide injection for chronic weight management at the 3 MG maintenance dose) do NOT appear in any of the 42 pages of the Alaska Medicaid PDL effective March 1, 2026. They are absent from the HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS class on page 6 (where their molecular siblings appear). They are absent from any “Obesity” class — there is no such PDL class.

Their absence is the operative exclusion mechanism. Alaska does not need to publish an affirmative categorical “weight-loss drugs are not covered” sentence because the PDL operates as a closed formulary at the preferred-tier level — drugs not on the PDL face the General Prior Authorization Form non-preferred pathway, and clinical-justification review at the Prime Therapeutics Clinical Call Center applies. For Wegovy, Zepbound, and Saxenda, no Alaska-specific PA criteria have been published, and no Alaska-specific carve-out for any of the FDA-label-restricted indications (SELECT/MACE, SURMOUNT-OSA, MASH, pediatric) has been published in publicly available documentation.

2.3 What this means in practice

A prescriber submitting a General PA Form for Wegovy, Zepbound, or Saxenda for an Alaska Medicaid beneficiary should expect: (1) the drug is not on the PDL in any class; (2) no Alaska-specific clinical criteria have been published; (3) clinical-justification review will route to Prime Therapeutics Clinical Call Center adjudication; (4) federal-floor indications (SELECT/MACE Wegovy, SURMOUNT-OSA Zepbound) should be honored per 42 U.S.C. § 1396r-8 federal requirements, but no Alaska policy bulletin operationalizing the federal floor was located in this verification. Best practice: call (800) 331-4475 before submitting the PA to verify whether Alaska is honoring the federal floor and what documentation is required.

3. The Alaska Medicaid General Prior Authorization Form

Alaska Medicaid uses a single General Prior Authorization Form for ALL non-preferred drugs across all therapeutic classes — there are no drug-specific PA forms. This contrasts with Mississippi Pattern #35 (GLP-1-specific PA form with pediatric ages 12+ pathway), California Medi-Cal (drug-specific PA forms for Wegovy MASH), and Texas Medicaid (drug-specific PA forms for the AOM molecules) — all of which use drug-specific PA forms. Alaska’s consolidated General PA form architecture makes the clinical-justification narrative more important for prescribers.

3.1 Form identity and access

The form is the Alaska Medicaid General Prior Authorization Form (Revision Date 10/03/2022). Two equivalent URLs:

• health.alaska.gov/media/zktjzc5r/ak_general_pa_form.pdf (Alaska DOH-hosted)
• ak.primetherapeutics.com/provider/external/medicaid/ak/doc/en-us/AKRx_PAform_general.pdf (Prime Therapeutics-hosted)

The Alaska DOH submission landing page is health.alaska.gov/dhcs/Pages/pharmacy/medpriorauthoriz.aspx.

3.2 Required fields verbatim from the form

• Requestor Information: name, title
• Member Information: last name, first name, Medicaid ID number, date of birth, sex, phone
• Prescriber Information: name, NPI, specialty, phone, fax
• Pharmacy Information: name, NPI, phone, fax
• Drug Information: drug name, NDC, strength, dosage form, dosage schedule, quantity, day supply, physician-administered Yes/No
• Clinical Information:
  1. Primary Diagnosis
  2. Other Diagnoses
  3. Current Medications
  4. Medical Justification (including previous failed therapies with dates)
• Attachments box

The attestation block verbatim:

“I hereby certify that this treatment is indicated and necessary and meets the guidelines for use as outlined by Alaska Medicaid.”

3.3 Submission contacts verbatim from the form

• Fax: (888) 603-7696
• Phone (Prime Therapeutics Clinical Call Center): (800) 331-4475
• Mail: Prime Therapeutics Management LLC, Attn: GV – 4201, P.O. Box 64811, St. Paul, MN 55164-0811

3.4 Adjudication timeframe

UNVERIFIED. Alaska DOH and Prime Therapeutics publicly available documentation does not state a specific PA adjudication turnaround for the General PA Form. The federal floor per 42 CFR § 431.221 is 24 hours for urgent requests and 14 days for standard requests. Prescribers seeking time-sensitive adjudication should call the Clinical Call Center at (800) 331-4475 directly to discuss expedited review and document the call in the clinical narrative.

3.5 Practical clinical-justification narrative for AOM PA submission

Because Wegovy, Zepbound, and Saxenda are absent from the Alaska PDL and no Alaska-specific clinical criteria exist for any indication, the clinical-justification narrative is the operative gate. Prescribers should structure the narrative around:

• FDA-label indication: SELECT/MACE (Wegovy, March 2024), SURMOUNT-OSA (Zepbound, December 2024), MASH (Wegovy, August 2025), pediatric ages 12+ (Wegovy, STEP TEENS). Cite the federal-floor requirement under 42 U.S.C. § 1396r-8.
• ICD-10 code: I25.10 (atherosclerotic heart disease) or I63.9 (cerebral infarction) for MACE; G47.33 (obstructive sleep apnea) for OSA; K75.81 (NASH) or K76.0 (fatty liver) for MASH; E66.x with age-specific BMI percentile documentation for pediatric obesity.
• Baseline objective data: BMI, A1c (to confirm absence of T2D for SELECT/MACE), AHI for OSA, fibrosis biomarker (FibroScan / ELF score / MR-PDFF) for MASH.
• Step-therapy or prior-therapy failure: Document any prior obesity / cardiometabolic medication trials and outcomes. Even though no Alaska-specific step-therapy is published, demonstrating that less expensive alternatives have failed strengthens the General PA Form clinical-justification narrative.
• Specialist consultation note: Cardiology for SELECT/MACE; sleep medicine for SURMOUNT-OSA; hepatology / gastroenterology / endocrinology for MASH. Specialist involvement is standard practice and should be documented.

4. Appeals — the Fair Hearing pathway

Alaska Medicaid uses a Fair Hearing appeal architecture administered through the Division of Public Assistance with hearings handled by an external vendor, Gainwell Technologies, and routed to the Office of Administrative Hearings (OAH) at oah.doa.alaska.gov.

4.1 Filing deadline

The Alaska DOH Notice of Recipient Fair Hearing Rights (Revised 09/13/2024) verbatim:

“You must submit your request within 30 days of the date on this letter under the authority of 7 AAC 49.030. Per 42 CFR § 431.224 an expedited hearing may be requested if the time otherwise permitted for a hearing would jeopardize your life, health, or ability to attain, maintain, or regain maximum function.”

Filing deadline: 30 days from the date on the decision letter, under the authority of 7 AAC 49.030. Expedited hearing: available if delay would jeopardize life, health, or ability to attain, maintain, or regain maximum function, per 42 CFR § 431.224.

4.2 Submission methods verbatim

• Mail: Fair Hearings, P.O. Box 240808, Anchorage, AK 99524
• Fax: (907) 644-8126
• Email: fairhearings@gainwelltechnologies.com
• Telephone: (907) 644-6800, Option 2 → Option 3 → Option 2
• Recipient Helpline: (800) 780-9972

4.3 Continuation of benefits during appeal

The Alaska DOH Notice of Recipient Fair Hearing Rights verbatim:

“If you are currently receiving benefits and you request a hearing, your benefits may be automatically continued while you wait for the hearing decision... If you continue to receive benefits and the hearing authority determines the Department was correct to stop or reduce your benefits, you may be required to repay the cost of those services under the authority of 42 C.F.R. 431.230 (b), 7 AAC 49.190, and 7 AAC 49.200.”

4.4 OAH cascade and Superior Court review

The Division of Public Assistance must refer the hearing request to the Office of Administrative Hearings (OAH) within 10 days. The OAH hearing must be resolved within 90 days. Further appeal to the Alaska Superior Court is available within 30 days of the OAH decision. The OAH is administratively independent from DPA, providing a separation-of-powers safeguard within the executive branch — an architectural feature shared with Montana’s DPHHS Office of Administrative Hearings (Pattern #46) and similar to South Dakota’s Office of Administrative Hearings (Pattern #45).

4.5 Free legal assistance

• Alaska Legal Services: (888) 478-2572 or (907) 272-9431
• Disability Law Center of Alaska: (800) 478-1234 or akpa@dlcak.org

4.6 Practical denial-recovery strategy

1. First, call the Prime Therapeutics Clinical Call Center at (800) 331-4475. Many denials are documentation deficiencies recoverable via re-submission of the General PA Form with additional clinical evidence (e.g., missing specialist consultation, missing baseline AHI, missing fibrosis biomarker).
2. If the denial is substantive (formulary-absence based for Wegovy / Zepbound / Saxenda), re-submit the General PA Form with the federal-floor citation. For Wegovy SELECT/MACE: cite 42 U.S.C. § 1396r-8 and the March 2024 FDA label expansion. For Zepbound SURMOUNT-OSA: cite the December 2024 FDA label expansion.
3. If re-submission fails, file the Fair Hearing request within 30 days of the denial letter date. Use 7 AAC 49.030 as the authority. Continuation of benefits is automatic unless you opt out (and subject to repayment if the denial is upheld).
4. For expedited review, cite 42 CFR § 431.224. Document the medical urgency that would jeopardize life, health, or ability to attain, maintain, or regain maximum function.
5. Contact Alaska Legal Services at (888) 478-2572 or Disability Law Center at (800) 478-1234 for representation if the case involves complex eligibility or AI/AN-specific considerations.

5. FFS-only architecture — one of a small handful of states without Medicaid MCOs

Alaska runs Medicaid on a fee-for-service basis — the state does NOT operate full-risk Medicaid managed care organizations (MCOs). A “voluntary coordinated care initiative” exists as a quality-improvement and care-coordination overlay, but there are no risk-based MCO contracts. This makes Alaska one of a small handful of states without Medicaid MCOs — comparable architecturally to Vermont (Pattern #41, FFS-only with no MCOs), South Dakota (Pattern #45, FFS-only with OptumRx pharmacy claims processor), Wyoming, and a few others.

Operational implications for GLP-1 coverage:

• Single statewide PDL covers 100% of the 231,000+ Medicaid/CHIP enrollees. There is no plan-by-plan formulary fragmentation, no MCO-specific carve-out, and no “different MCOs cover different drugs” problem that exists in MCO-dominant states (e.g., Florida, Texas, California).
• Single PA pathway via the General Prior Authorization Form. There is no MCO-specific PA form, no MCO-specific clinical criteria, and no MCO-specific contact directory. Every Alaska Medicaid PA goes through Prime Therapeutics Clinical Call Center adjudication.
• Single Fair Hearing pathway via Gainwell Technologies and the OAH. There is no MCO-internal appeal step (which Mississippi, Texas, and other MCO-dominant states require before reaching the state fair hearing).
• Simplified provider experience. Alaska prescribers do not need to maintain multiple MCO portals, multiple PA workflows, or multiple clinical-criteria libraries. The Prime Therapeutics Drug Lookup Tool at ak.primetherapeutics.com/provider/ is the single authoritative resource.

The FFS-only architecture also means that the categorical AOM exclusion (Wegovy / Zepbound / Saxenda absent from the PDL) cannot be overridden by an MCO-specific carve-out — there is no MCO with discretion to add the AOM molecules to its own internal formulary. The exclusion is uniform statewide.

6. Geography — the largest state by area in the US

Alaska covers 663,267 square miles — approximately 17% of total US land area, larger than Texas, California, and Montana combined. The total population is approximately 740,000, yielding a population density of about 1.3 people per square mile — the lowest in the United States and roughly 1/70th of the US average density of about 94 people per square mile.

Pharmacy logistics, mail-order coverage, and telehealth-only access are uniquely important. Village clinics in communities like Anaktuvuk Pass, Kaktovik, Diomede, Atqasuk, and Shishmaref serve populations that are accessible only by plane or boat for much of the year. Many rural Alaska Medicaid beneficiaries cannot drive to a retail pharmacy — mail-order via the US Postal Service Bypass Mail program or via commercial air-freight pharmacy delivery is operationally essential. Telehealth consultation with Anchorage-based or Lower-48-based specialists is the norm rather than the exception for many beneficiaries.

6.1 Operational implications for prescribers and patients

• PCP-issued GLP-1 is often the most accessible route for both T2D-indicated coverage and cash-pay obesity-indicated use. Specialty endocrinology, cardiology, hepatology, and sleep medicine subspecialty access is thin outside Anchorage, Fairbanks, Juneau, and Wasilla.
• Mail-order pharmacy is operationally important even for in-state covered prescriptions. Alaska Medicaid’s preferred mail-order pharmacy networks should be confirmed with Prime Therapeutics (800-331-4475) before assuming any specific pharmacy is in-network.
• Telehealth specialist consultation via licensed Alaska providers can substitute for in-person endocrinology, sleep medicine, or hepatology visits in many cases. The Alaska State Medical Board maintains licensure records for telehealth-capable specialists.
• Cash-pay direct-to-consumer GLP-1 (NovoCare, LillyDirect, LegitScript-approved compounded telehealth) is operationally important given sparse-geography access. Direct shipping to rural Alaska addresses is generally available; village postal codes, P.O. boxes, and bypass mail constraints can affect delivery and should be verified before ordering.

7. Tribal Health Compact and 100% FMAP overlay

Alaska is home to 229+ federally recognized tribes — more than any other state. The Alaska Area Indian Health Service (IHS) and the Alaska Native Tribal Health Consortium (ANTHC), headquartered in Anchorage, operate a network of tribally managed hospitals, tribal health centers, and village clinics that together constitute the largest tribally managed health system in the country.

7.1 The Alaska Tribal Health System

Tribally managed hospitals (8): Alaska Native Medical Center (Anchorage), Samuel Simmonds Memorial Hospital (Utqiagvik / Barrow), Yukon-Kuskokwim Delta Regional Hospital (Bethel), Bristol Bay Area Health Corporation hospital (Dillingham), Maniilaq Health Center (Kotzebue), Norton Sound Regional Hospital (Nome), Mt. Edgecumbe Medical Center (Sitka), and Wrangell SEARHC facility. Plus 72 tribal health centers and 148 village clinics serving the most remote Alaska Native communities.

7.2 100% FMAP for AI/AN services

Services provided to American Indian / Alaska Native Medicaid beneficiaries at IHS / tribal facilities receive 100% Federal Medical Assistance Percentage — the state pays no share. Per the CMS Medicaid Indian Health Program Alaska guidance at medicaid.gov/medicaid/indian-health-medicaid/downloads/alaska.pdf and the MACPAC report on Medicaid’s Role in Health Care for American Indians and Alaska Natives at macpac.gov, AI/AN Medicaid beneficiaries are exempt from premiums and copays, and under 2026 expansion-eligibility redetermination rules effective December 31, 2026 are exempt from the 6-month redetermination cycle that applies to other expansion enrollees.

7.3 The AOM exclusion still applies

Despite the 100% FMAP and zero-cost-share advantages for AI/AN Medicaid beneficiaries, the categorical AOM exclusion still applies to drugs dispensed through IHS-Medicaid billing pathways. An Alaska Native Medicaid beneficiary filling a prescription at ANMC, a tribal health center pharmacy, or a village clinic faces the same PDL-absence exclusion of Wegovy, Zepbound, and Saxenda. The 100% FMAP advantage operates on the federal-state cost-sharing axis — it does not change which drugs are on the formulary.

UNVERIFIED: Whether tribally operated 638-contract pharmacies (under the Indian Self-Determination and Education Assistance Act) have separate formulary access or AOM-coverage flexibility distinct from the Alaska Medicaid PDL is not addressed in publicly available CMS Medicaid Indian Health Program Alaska documentation. Readers should consult ANTHC pharmacy services directly or the Alaska Federation of Natives Health Department for jurisdiction-specific guidance.

8. Medicaid expansion via executive action — the Walker enactment

Alaska expanded Medicaid effective September 1, 2015 via executive action by Gov. Bill Walker (announced July 16, 2015), making AK the 30th expansion state. Walker’s expansion is politically distinctive: most ACA-expansion states adopted expansion via legislative action or ballot initiative. Walker invoked the Department of Health and Social Services’ regulatory authority to extend Medicaid eligibility to adults 19-64 up to 138% of the federal poverty level without an affirmative legislative vote.

The expansion survived legislative challenge in 2015-2016 and has remained in place under the Dunleavy administration since 2018. The Dunleavy administration has not rolled back expansion but has proposed work requirements via the FY2025-FY2045 long-term Medicaid forecast at health.alaska.gov/media/ya5hhm30/long-term-forecast-of-medicaid-enrollment-and-spending-in-alaska-fy2025fy2045.pdf. The 2024 Annual Medicaid Reform Report at health.alaska.gov/media/alpdbqal/2024-annual-medicaid-reform-report.pdf provides additional context on reform proposals.

8.1 Enrollment trajectory

Total Medicaid/CHIP enrollment is approximately 231,000 as of January 2026. ACA expansion enrollment is 61,388 as of February 2026. Approximately 1 in 3 Alaskans are on Medicaid; by state fiscal year 2024, approximately 40% of Alaskans were enrolled in Medicaid for all or part of the year. The Tribal Health Reform Resource Center expansion fact sheets at tribalhealthreform.nihb.org/medicaid-expansion-fact-sheets/ document the AI/AN component of the expansion population.

8.2 The categorical AOM exclusion in an expansion state

Alaska joins the pattern of expansion states that have NOT extended FFS Medicaid coverage to obesity-indicated GLP-1s — distinct from the approximately 13 covering states in the KFF January 2026 cohort. Closest peer expansion states with categorical AOM exclusions: Arizona (Pattern, AHCCCS Provider Billing Manual Chapter 12 categorical exclusion); West Virginia (Pattern #36, categorical exclusion with active Wegovy CV + Zepbound OSA + Wegovy MASH carve-outs via WVU RDTP); Montana (Pattern #46, categorical exclusion with carve-outs UNVERIFIED). The pattern is consistent: expansion does not automatically produce AOM coverage; the AOM coverage decision is independent of the expansion decision.

9. Legislative history — the Alaska bill landscape

No Alaska bills have been identified in the 33rd or 34th Legislature directly addressing GLP-1 or AOM Medicaid coverage as of May 15, 2026. The Alaska State Legislature bill explorer is at akleg.gov.

9.1 Tangentially related activity

• HB 346 (33rd Legislature, 2023-2024): addressed health insurance coverage for gastric bypass surgery for obesity. The bill applies to private insurers, NOT Medicaid. Text at akleg.gov/basis/Bill/Text/23?Hsid=HB0346A.
• Alaska Division of Insurance 2024 EHB public input: considered adding weight-loss drug coverage to the individual / small-group ACA marketplace Essential Health Benefits benchmark plan. The proposal targets the commercial market, NOT Medicaid.

9.2 The absence of an AOM-mandate bill

Alaska does not have a clear analog to Maine LD 480 (Ought-Not-To-Pass March 20, 2025), Nebraska LB907 (Indefinitely Postponed), Vermont H.765 / S.164 (stalled in committee), Montana SB 417 (died 11-1 in committee March 1, 2025), North Dakota HB 1451 / HB 1452 (failed 12-81 / 11-82 in House on February 12, 2025), or Kansas HAWK Act HB 2375 (died in committee). The AOM-mandate legislative wave that has touched many peer states in the 50-state series has not yet reached the Alaska Legislature in a verified form.

34th Legislature bill scan is UNVERIFIED. Readers should track bills.akleg.gov for current bill status — future sessions may produce a comparable AOM-mandate bill given continued GLP-1 utilization growth.

10. T2D-indicated GLP-1 coverage detail

Type 2 diabetes-indicated GLP-1 receptor agonists are PDL preferred “ON” status on the Alaska Medicaid PDL effective March 1, 2026, page 6, HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS class. Preferred status (effective November 1, 2025) covers:

• OZEMPIC (semaglutide subcutaneous) at all FDA-labeled strengths
• MOUNJARO (tirzepatide subcutaneous) at all FDA-labeled strengths
• RYBELSUS (oral semaglutide tablets) at all FDA-labeled strengths
• TRULICITY (dulaglutide pen) at all FDA-labeled strengths
• VICTOZA (liraglutide)
• BYDUREON BCISE (exenatide extended-release)
• ADLYXIN (lixisenatide)

Specific clinical edits (HbA1c thresholds, step-therapy requirements, quantity limits) are UNVERIFIED in publicly available Alaska DOH or Prime Therapeutics documentation. The PDL status “ON” indicates preferred-tier coverage; absence of an explicit non-preferred or off-PDL designation suggests standard T2D-indicated use should not require a PA at the preferred-tier formulary gate. The provider-gated Drug Lookup Tool at ak.primetherapeutics.com/provider/ is the authoritative source for operative clinical criteria.

10.1 Prescriber documentation checklist for T2D-indicated GLP-1 prescribing

• Type 2 diabetes diagnosis with ICD-10 code (E11.x for Type 2 diabetes mellitus)
• Baseline HbA1c and most recent HbA1c (preferably within 90 days)
• Prior medication history including metformin trial and outcome
• Trial history with second-line classes (sulfonylurea, DPP-4 inhibitor, SGLT-2 inhibitor) if relevant
• Clinical rationale for GLP-1 class selection (cardiovascular risk, renal protection, weight comorbidity, hypoglycemia avoidance)
• Specific drug requested and dosing

Because all seven incretin agents listed on the PDL are preferred “ON” status, prescribers have full flexibility within the T2D-indicated class. The selection should reflect FDA-label fit, patient preference (injectable vs. oral), prior-trial history, and cardiometabolic comorbidities (Wegovy-equivalent semaglutide is not on the PDL; T2D-indicated Ozempic is the operative semaglutide pathway; tirzepatide T2D-indicated Mounjaro is the operative tirzepatide pathway).

11. Pattern #49 vs. peer patterns in the 50-state series

Alaska Pattern #49 sits within the categorical-exclusion architectural family. Architecturally distinctive features that distinguish it from peers:

11.1 vs. Montana Pattern #46

Both states have categorical AOM exclusions. Differences:

• Codification style: MT codifies its exclusion verbatim in the DPHHS Pharmacy Program “Not Covered” bucket (“weight-loss medications”) and in the Prescription Drug Program Manual (“The program explicitly does not reimburse for drugs prescribed for weight reduction”). AK operates by absence — no equivalent affirmative sentence; the AOM molecules simply do not appear on the PDL.
• PA processor: MT uses Mountain-Pacific Quality Health (MPQH), a non-profit QIO. AK uses Prime Therapeutics Medicaid Administration, a commercial PBM (formerly Magellan Rx).
• PA form architecture: MT has a “Request for Drug Prior Authorization” form with class-specific clinical criteria embedded. AK has a single General PA Form covering all non-preferred drugs across all classes with no drug-specific forms.
• Delivery system: MT uses PCCM (Passport to Health) on top of FFS. AK is pure FFS with a voluntary coordinated care initiative.
• Geography + tribal: AK is materially larger (663,267 sq mi vs. 147,040 sq mi) and has materially more tribal density (229+ federally recognized tribes vs. 7 in MT). AK’s 100% FMAP Tribal Health Compact and ANTHC overlay are unique in the series.
• 2025 legislative history: MT had decisive SB 417 rejection (11-1 March 1, 2025; died May 23, 2025). AK has no equivalent AOM-mandate bill identified as of May 15, 2026.

11.2 vs. North Dakota Pattern #44

Both states share Northern Plains / Mountain West sparse-geography context and tribal-health overlap. Differences:

• Carve-out architecture: ND is a middle-ground “covered for everything except obesity” state with explicit carve-outs for Wegovy SELECT/MACE, Wegovy MASH, Zepbound OSA, Ozempic / Victoza for antipsychotic-induced weight gain, and Imcivree for genetic obesity disorders. AK has no published carve-outs — the federal floor for SELECT/MACE and SURMOUNT-OSA is UNVERIFIED in publicly available Alaska policy documentation.
• Legislative posture: ND HB 1451 / HB 1452 FAILED 12-81 / 11-82 on the House floor (February 12, 2025) — the most decisive legislative no-vote in the series. AK has no comparable AOM-mandate bill.
• Delivery system: ND uses FFS-dominant traditional Medicaid (74% of spending FFS) plus BCBSND-only Medicaid Expansion via a 1915(b) waiver. AK is pure FFS with no MCO.
• Commercial market: ND’s 2025 EHB Benchmark Plan covers GLP-1s for morbid obesity in the commercial individual / small-group market — inverse of Medicaid posture. AK has not yet implemented an equivalent commercial-market mandate (the 2024 Division of Insurance public input was the closest activity).

11.3 vs. South Dakota Pattern #45

Both states operate functional AOM exclusions by absence rather than by affirmative categorical sentence. Differences:

• Exclusion mechanism: SD operates exclusion-by-absence at the PA-form-pre-coding level — the OptumRx SD-specific GLP-1 Agonists PA Request Form limits the diagnosis-checkbox to T2D or “Other diagnosis” with no obesity / E66 ICD-10 pathway. AK operates exclusion-by-absence at the PDL-listing level — the AOM molecules simply do not appear on the formulary; there is no drug-specific GLP-1 PA form.
• PA processor: SD uses OptumRx as the pharmacy claims processor (effective November 13, 2017). AK uses Prime Therapeutics Medicaid Administration.
• Expansion path: SD adopted expansion via ballot initiative (Constitutional Amendment D, November 8, 2022, 56.21% yes, effective July 1, 2023); SD HJR 5001 referred Constitutional Amendment I to the November 3, 2026 ballot to condition expansion on FMAP ≥ 90%. AK adopted expansion via executive action (Gov. Walker, September 1, 2015) — no comparable constitutional-amendment trigger.
• Adjudication timeframe: SD Pharmacy Services Manual verbatim “Most PA requests are adjudicated within 72 hours. A clean request is often adjudicated in less than 24 hours.” AK adjudication timeframe is UNVERIFIED.
• Appeals deadline: SD requires hearing request within 30 days of decision date to OAH; ALJ decision within 90 days. AK requires hearing request within 30 days of decision letter date under 7 AAC 49.030; OAH resolution within 90 days. Both 30/90 days — structurally identical.

11.4 vs. Rhode Island Pattern #40, Vermont Pattern #41, and Kansas Pattern #43

RI Pattern #40 is the first state in the series with active GLP-1 coverage plus governor-proposed October 1, 2026 sunset (inverse coverage posture to AK — RI covers GLP-1s for obesity; AK does not). VT Pattern #41 is the closest peer architecturally for the “categorical exclusion + drug-specific carve-out PA forms” pattern, but VT has explicit Wegovy MACE / Wegovy MASH / Zepbound OSA carve-outs operationalized via drug-specific PA forms; AK has neither the carve-out forms nor the published carve-out criteria. KS Pattern #43 is the inverse trajectory — positive-coverage non-expansion state that LOOSENED criteria in 2024-2025 by de-listing Wegovy + Zepbound from Table 4 (BMI ≥ 40 severe-obesity gate eliminated). AK is neither covering nor loosening — the categorical exclusion stands.

12. Cash-pay and compounded options for Alaska patients

Alaska Medicaid beneficiaries who do not qualify for T2D coverage and who face the categorical AOM exclusion have several practical paths.

12.1 Manufacturer cash-pay

• Novo Nordisk NovoCare Wegovy: tiered pricing as of May 15, 2026. The $499 baseline was retired in May 2026; current tiers are $199-$349 per month for standard pen formats, $399 per month for the high-dose pen, and $149 per month for oral semaglutide tablets.
• LillyDirect Zepbound vials: $299-$699 per month depending on dose strength.
• LillyDirect Foundayo (orforglipron, FDA-approved April 1, 2026): $149 per month self-pay.

12.2 Patient assistance programs

• Novo Nordisk Patient Assistance Program for Wegovy — income-tested
• Lilly Cares for Zepbound — income-tested

12.3 LegitScript-approved compounded telehealth

Typical market prices as of May 2026: $99-$199 per month for compounded semaglutide and $149-$249 per month for compounded tirzepatide. Note the FDA tirzepatide compounding-resolved status (October 2024) and semaglutide compounding-resolved status (February 2025) mean new compounded prescriptions for these molecules now require documented patient-specific clinical need beyond the previous shortage-based justification. Compounded products are not FDA-approved finished pharmaceutical products and are not on the Alaska Medicaid PDL; they are cash-pay only.

12.4 Rural Alaska shipping considerations

Direct mail-order shipping from NovoCare, LillyDirect, and LegitScript-approved telehealth platforms to bush addresses is generally available, but should be confirmed before ordering. Village postal codes, P.O. boxes, USPS Bypass Mail constraints, and air-freight schedules can affect delivery timing — some remote communities receive mail only twice weekly, and refrigerated medication delivery may require coordination with local clinic refrigeration. Telehealth platforms accustomed to rural / remote shipping include Sequence (Wegovy via Novo Nordisk), Ro (Wegovy + Zepbound), and Henry Meds (compounded only).

13. Step-by-step action plan for Alaska Medicaid beneficiaries

1. Confirm your Medicaid eligibility status. Total enrollment is 231,000+ (January 2026); expansion is 61,388 (February 2026). The Division of Public Assistance administers eligibility; call (800) 780-9972 (Recipient Helpline) to confirm your status.
2. Verify whether your prescription is on the Alaska Medicaid PDL. The PDL effective March 1, 2026 is at health.alaska.gov/media/yaon3cxf/pdl-effective-date_20260301v11.pdf. T2D-indicated GLP-1s (Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza, Bydureon BCISE, Adlyxin) are preferred “ON” status; AOM-indicated GLP-1s (Wegovy, Zepbound, Saxenda) are absent.
3. For T2D-indicated coverage: work with your prescriber to document the diagnosis, HbA1c, prior medication history, and clinical rationale. Preferred-tier coverage should not require a PA at the formulary gate. If clinical edits trigger PA review, the General Prior Authorization Form route applies.
4. For AOM-indicated coverage: prepare for a difficult PA process. The AOM molecules are absent from the PDL, no Alaska-specific clinical criteria exist, and the federal-floor indications (Wegovy SELECT/MACE, Zepbound SURMOUNT-OSA) have not been operationalized via Alaska policy bulletin. Best practice: call the Prime Therapeutics Clinical Call Center at (800) 331-4475 before submitting the PA to verify whether Alaska is honoring the federal floor for your indication.
5. Submit the General PA Form. Form at health.alaska.gov/media/zktjzc5r/ak_general_pa_form.pdf. Fax to (888) 603-7696. Document the FDA-label indication, ICD-10 code, baseline objective data, prior-therapy history, specialist consultation, and (for federal-floor indications) cite 42 U.S.C. § 1396r-8 and the relevant FDA label expansion.
6. If denied, file a Fair Hearing request within 30 days of the decision letter date. Use 7 AAC 49.030 as the authority. Submission methods: mail Fair Hearings, P.O. Box 240808, Anchorage, AK 99524; fax (907) 644-8126; email fairhearings@gainwelltechnologies.com; phone (907) 644-6800 (Option 2 → 3 → 2).
7. Consider free legal assistance. Alaska Legal Services at (888) 478-2572 or (907) 272-9431. Disability Law Center of Alaska at (800) 478-1234 or akpa@dlcak.org.
8. If the Fair Hearing fails, consider Superior Court appeal. Filing deadline: 30 days from the OAH decision date.
9. While the PA / appeal is pending, evaluate cash-pay alternatives. NovoCare Wegovy, LillyDirect Zepbound, LillyDirect Foundayo (orforglipron $149/month), and LegitScript-approved telehealth compounded GLP-1s. Confirm rural Alaska shipping before ordering.
10. For AI/AN beneficiaries, consult ANTHC pharmacy services directly to verify whether 638-contract pharmacy formulary access is materially different from the state PDL. The 100% FMAP advantage does not change which drugs are on the formulary, but specific tribal-pharmacy guidance may be available.

14. Prescriber workflow for Alaska Medicaid GLP-1 PA submission

Alaska Medicaid prescribers should structure their workflow around the single General PA Form architecture and the absence of drug-specific clinical criteria for the AOM molecules.

1. Confirm the patient’s Medicaid status and eligibility category via the Alaska Medical Assistance Provider portal.
2. Verify PDL status for the requested drug. T2D-indicated incretins are preferred “ON” status; AOM-indicated molecules are absent.
3. For PDL preferred drugs: standard e-prescribing routes to the patient’s chosen pharmacy. Clinical edits (HbA1c thresholds, quantity limits) may trigger PA review — these are UNVERIFIED at the publicly available documentation level; the Prime Therapeutics Drug Lookup Tool at ak.primetherapeutics.com/provider/ is the authoritative provider-gated resource.
4. For non-PDL / non-preferred drugs (including all AOM molecules): complete the General Prior Authorization Form. Required field completeness checklist:
   • Requestor name and title
   • Member last/first name, Medicaid ID, DOB, sex, phone
   • Prescriber name, NPI, specialty, phone, fax
   • Pharmacy name, NPI, phone, fax
   • Drug name, NDC, strength, dosage form, dosage schedule, quantity, day supply, physician-administered Y/N
   • Primary diagnosis (use specific ICD-10 code)
   • Other diagnoses
   • Current medications
   • Medical justification including previous failed therapies WITH DATES
   • Attestation block signed
5. Attach supporting documentation: recent labs (HbA1c, lipid panel, liver function tests as relevant); FibroScan / ELF / MR-PDFF for MASH; in-lab polysomnography report with AHI for OSA; cardiology consultation note for SELECT/MACE; pediatric growth chart with BMI percentile for pediatric obesity (Wegovy STEP TEENS).
6. Fax to (888) 603-7696. For status checks, call (800) 331-4475.
7. If denied: review the denial rationale via Clinical Call Center. Most denials are documentation deficiencies recoverable via re-submission with additional clinical evidence. If the denial is substantive (formulary-absence based), prepare the patient for a Fair Hearing filing.

15. Three patient narratives illustrating Pattern #49

15.1 Anchorage resident with Type 2 diabetes seeking Mounjaro

A 52-year-old Anchorage resident with Type 2 diabetes mellitus (E11.9) and HbA1c of 8.4% on metformin monotherapy presents for intensification. The endocrinologist e-prescribes Mounjaro 2.5 MG/0.5 ML weekly. Mounjaro is on the Alaska Medicaid PDL effective March 1, 2026, page 6, as preferred “ON” status. The prescription should fill at the patient’s preferred retail pharmacy without PA at the formulary gate. If clinical edits (HbA1c-threshold, quantity limit) trigger PA review, the General PA Form route applies. Estimated turnaround: standard federal floor of 14 days; clean requests adjudicated faster per Prime Therapeutics Clinical Call Center practice.

15.2 Fairbanks resident with cardiovascular disease seeking Wegovy SELECT/MACE

A 64-year-old Fairbanks resident with prior myocardial infarction (I25.10), BMI 31, A1c 5.7% (no T2D), on aspirin + atorvastatin presents for SELECT/MACE-indicated Wegovy 2.4 MG weekly. Wegovy is absent from the Alaska Medicaid PDL. The cardiologist completes the General PA Form citing 42 U.S.C. § 1396r-8 and the March 2024 FDA label expansion for Wegovy MACE risk reduction. Documentation includes the post-MI cardiology consult, the recent BMI measurement, the normal A1c confirming absence of T2D, the SELECT trial inclusion criteria narrative, and the federal-floor citation. The PA is faxed to (888) 603-7696. Outcome UNVERIFIED — no Alaska-specific policy bulletin operationalizing the SELECT/MACE federal floor was located. Best practice: pre-call the Clinical Call Center at (800) 331-4475 before submission to verify Alaska’s federal-floor honoring posture and what documentation is required. If denied, file Fair Hearing within 30 days.

15.3 Bethel-area Alaska Native resident at ANTHC tribal hospital seeking Zepbound SURMOUNT-OSA

A 47-year-old Alaska Native resident of a Yukon-Kuskokwim Delta village, seen at the Yukon-Kuskokwim Delta Regional Hospital (ANTHC), with BMI 38, in-lab polysomnography AHI 28 (moderate-to-severe OSA, G47.33), on CPAP for 6 months without adherence (interface intolerance), presents for SURMOUNT-OSA-indicated Zepbound 5 MG weekly. The patient is on Alaska Medicaid as an AI/AN expansion enrollee — services at ANTHC facilities receive 100% FMAP. Zepbound is absent from the Alaska Medicaid PDL. The hospitalist completes the General PA Form citing 42 U.S.C. § 1396r-8 and the December 2024 FDA label expansion for Zepbound SURMOUNT-OSA. Documentation includes the polysomnography report, CPAP adherence documentation, BMI, and the federal-floor citation. The PA is faxed to (888) 603-7696. Outcome UNVERIFIED — no Alaska-specific policy bulletin operationalizing the SURMOUNT-OSA federal floor was located. The 100% FMAP advantage does not affect the formulary-level coverage decision — the AOM exclusion still applies. If denied, file Fair Hearing within 30 days via Gainwell Technologies; consider Alaska Legal Services consultation for the AI/AN-specific aspects of the case.

16. UNVERIFIED items honestly flagged

This article applies the YMYL 125% accuracy standard and flags every item that could not be verified verbatim from primary sources in the May 15, 2026 verification cycle:

1. Wegovy CV (SELECT/MACE) PA criteria. The March 2024 FDA label expansion is a federal floor under 42 U.S.C. § 1396r-8, but no Alaska-specific PA criteria or policy bulletin operationalizing the federal floor was located. Wegovy is absent from the PDL in any class.
2. Zepbound OSA (SURMOUNT-OSA) PA criteria. The December 2024 FDA label expansion is a federal floor, but no Alaska-specific PA criteria or policy bulletin was located. Zepbound is absent from the PDL.
3. Wegovy MASH PA criteria. The August 2025 FDA label expansion is recent; no Alaska-specific operationalization was located.
4. Wegovy pediatric (ages 12+) status. The STEP TEENS-supported FDA labeling for adolescent obesity exists; no Alaska-specific coverage pathway was located. EPSDT at 42 U.S.C. § 1396d(r) provides a federal floor for medical necessity in Medicaid beneficiaries under 21 — readers should pursue this regulatory anchor in pediatric PA submissions.
5. T2D GLP-1 step therapy and quantity limits. The PDL status “ON” (preferred) is verified for all seven incretins, but specific clinical edits (HbA1c thresholds, prior-metformin-trial requirements, monthly quantity limits) are UNVERIFIED in publicly available documentation. The Prime Therapeutics Drug Lookup Tool at ak.primetherapeutics.com/provider/ is the authoritative provider-gated source.
6. Standard PA adjudication timeframe. Federal floor per 42 CFR 431.221: 24 hours urgent / 14 days standard. Alaska-specific timeframe is UNVERIFIED.
7. 34th Legislature bill scan. No AOM-mandate bills identified, but a full scan of the 34th Legislature session is UNVERIFIED.
8. Complete 13-state KFF coverage cohort list. KFF identifies approximately 13 states covering GLP-1s for obesity under FFS Medicaid as of January 2026, but the complete list is UNVERIFIED in this article. Confirmed in cohort include MS Pattern #35, DE Pattern #42, KS Pattern #43, RI Pattern #40 (with proposed sunset).
9. PBM transition history. Magellan Medicaid Administration → Prime Therapeutics Medicaid Administration (Prime acquired Magellan Rx late 2022 for $1.35B) is verified. Earlier PBM history and the specific Gainwell role in Medicaid Fair Hearings (vs. claims processing) is UNVERIFIED.
10. Whether tribally operated 638-contract pharmacies have separate formulary access distinct from the state PDL is UNVERIFIED. Consult ANTHC pharmacy services or the Alaska Federation of Natives Health Department directly.
11. Whether Contrave (naltrexone/bupropion) and Qsymia (phentermine/topiramate) are covered under Alaska Medicaid in any form is UNVERIFIED — neither branded fixed-combination AOM appears in the published PDL.

17. Key takeaways

1. Alaska Medicaid does NOT cover Wegovy, Zepbound, or Saxenda for chronic weight management. The exclusion operates by absence from the Alaska Medicaid Preferred Drug List effective March 1, 2026 — the AOM molecules do not appear in any class of the 42-page PDL.
2. Alaska is NOT in the approximately 13-state KFF January 2026 coverage cohort. The categorical AOM exclusion stands in a Medicaid-expansion state — consistent with the pattern across Arizona, West Virginia, Tennessee, and other expansion states that have NOT extended FFS Medicaid coverage to obesity-indicated GLP-1s.
3. T2D-indicated GLP-1s are preferred and covered. Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza, Bydureon BCISE, and Adlyxin are all PDL “ON” status effective November 1, 2025.
4. FFS-only architecture with no MCOs. Single statewide PDL + single PA pathway covers 100% of the 231,000+ Medicaid/CHIP enrollees.
5. Largest geography in the US. 663,267 sq mi (~17% of US land area); ~1.3 people per square mile (lowest density in the US). Pharmacy logistics, mail-order, and telehealth dominate access.
6. 100% FMAP Tribal Health Compact. 229+ federally recognized tribes; Alaska Area IHS + ANTHC operate 8 tribally managed hospitals + 72 tribal health centers + 148 village clinics. AI/AN beneficiaries exempt from premiums, copays, and (effective December 31, 2026) the 6-month redetermination cycle.
7. Expansion via executive action. Gov. Walker’s September 1, 2015 unilateral expansion remains intact under the Dunleavy administration; 61,388 expansion enrollees as of February 2026.
8. Single General PA Form for ALL non-preferred drugs. No drug-specific PA forms. Clinical-justification narrative is the operative gate.
9. PBM is Prime Therapeutics Medicaid Administration. Formerly Magellan Medicaid Administration; Prime acquired Magellan Rx late 2022 for $1.35 billion. Clinical Call Center (800) 331-4475; PA fax (888) 603-7696.
10. Appeals: 30 days from decision letter under 7 AAC 49.030. Gainwell Technologies handles Fair Hearings. Expedited per 42 CFR § 431.224. OAH resolution within 90 days; Superior Court within 30 days thereafter.
11. No active AOM-mandate bill identified in the 33rd or 34th Legislature. Alaska has not seen a clear analog to Maine LD 480, Nebraska LB907, Montana SB 417, North Dakota HB 1451 / HB 1452, or Kansas HAWK Act HB 2375.
12. Cash-pay paths are operationally important. NovoCare Wegovy at $149-$399/month tiers (after May 2026 baseline retirement); LillyDirect Zepbound at $299-$699/month; LillyDirect Foundayo (orforglipron) at $149/month; LegitScript-approved compounded telehealth at $99-$249/month.

Related coverage

• Montana Medicaid GLP-1 Coverage (Pattern #46) — closest peer architecturally: sparse-geography categorical-exclusion state with IHS / tribal-health overlap; MT codifies the exclusion verbatim (“weight-loss medications” in the Not Covered bucket) while AK operates by PDL absence; MT uses MPQH (non-profit QIO) for PA processing, AK uses Prime Therapeutics (commercial PBM); MT had decisive 2025 SB 417 rejection (11-1 March 1, 2025), AK has no comparable AOM-mandate bill identified
• North Dakota Medicaid GLP-1 Coverage (Pattern #44) — opposite carve-out posture: ND covers Wegovy MACE + Wegovy MASH + Zepbound OSA + Ozempic/Victoza no-PA for antipsychotic-induced weight gain + Imcivree but NOT Wegovy/Zepbound/Saxenda for obesity; AK has no published carve-outs for the federal-floor indications; ND HB 1451 / HB 1452 FAILED 12-81 / 11-82 on House floor (most decisive legislative no-vote in series), AK has no comparable AOM-mandate bill
• South Dakota Medicaid GLP-1 Coverage (Pattern #45) — closest peer in the “exclusion by absence” architectural subgroup: both AK and SD operate functional AOM exclusion by absence rather than codified categorical sentence, both are FFS-only states; SD operates at the PA-form-pre-coding level (OptumRx SD-specific GLP-1 form pre-codes T2D only), AK operates at the PDL-listing level (AOM molecules simply not on the formulary; single General PA Form covers all classes); both 30-day appeal windows to OAH with 90-day ALJ resolution
• Kansas Medicaid GLP-1 Coverage (Pattern #43) — inverse trajectory: KS covers Wegovy + Zepbound for obesity at adult BMI ≥ 30 (no carve-out gymnastics needed) and LOOSENED criteria in 2024-2025 by de-listing both drugs from Table 4; AK is neither covering nor loosening — the categorical exclusion stands
• Rhode Island Medicaid GLP-1 Coverage (Pattern #40) — first state in series with active coverage + governor-proposed October 1, 2026 sunset (inverse coverage posture to AK)
• Vermont Medicaid GLP-1 Coverage (Pattern #41) — closest peer architecturally for FFS-only no-MCO categorical-exclusion state: VT excludes baseline AOM but operationalizes three FDA-label carve-outs (Wegovy MACE + Wegovy MASH + Zepbound OSA) via drug-specific PA forms; AK has neither the carve-out forms nor the published carve-out criteria
• Maine MaineCare GLP-1 Coverage (Pattern #39) — categorical exclusion with NO Wegovy MASH carve-out; LD 480 killed March 20, 2025
• Nebraska Medicaid GLP-1 Coverage (Pattern #38) — categorical exclusion with 45-74 age gate + 6-month MASH prerequisite; LB907 Indefinitely Postponed
• Utah Medicaid GLP-1 Coverage (Pattern #37) — legislative pilot-program coverage with 6/30/2026 sunset of in-lab attended PSG carve-out
• West Virginia Medicaid GLP-1 Coverage (Pattern #36) — categorical exclusion with Wegovy CV + Zepbound OSA + Wegovy MASH carve-outs via WVU RDTP — closest expansion-state peer for the categorical-exclusion architecture
• Mississippi Medicaid GLP-1 Coverage (Pattern #35) — only non-expansion southern positive-coverage state; SPA 23-0013 carve-back-in with pediatric ages 12+ pathway
• Delaware Medicaid GLP-1 Coverage (Pattern #42) — positive-coverage state with unified DMAP PDL across 3 MCOs (Wegovy + Saxenda preferred; Zepbound clinical-exception pathway); §1115 Diamond State Health Plan extended through December 31, 2028
• 50-state Medicaid GLP-1 coverage map — full series overview with pattern taxonomy
• GLP-1 insurance coverage hub — Medicare, Medicaid, and commercial coverage landscape
• GLP-1 insurance dropped coverage appeal playbook — denial-recovery patterns applicable across states

Primary sources

1. Alaska Department of Health — Medicaid Pharmacy & Therapeutics
2. Alaska Medicaid Preferred Drug List effective March 1, 2026 — 42 pages, posted January 23, 2026
3. Alaska Medicaid PDL landing
4. Alaska Medicaid Upcoming PDL effective June 1, 2026
5. Alaska Medicaid Prior Authorization Medication List
6. Alaska Medicaid General Prior Authorization Form (Rev 10/03/2022) — Alaska DOH-hosted
7. Alaska Medicaid General Prior Authorization Form (Prime Therapeutics-hosted)
8. Alaska DOH Medication Prior Authorization landing
9. Alaska Medicaid Prescription Drug Coverage (DPA Services)
10. Alaska DOH Notice of Recipient Fair Hearing Rights (Rev 09/13/2024)
11. Alaska Office of Administrative Hearings
12. Alaska Law Help — Fair Hearings (Medicaid)
13. KFF Medicaid Coverage and Spending on GLP-1s (January 2026)
14. KFF Medicaid in Alaska Fact Sheet (May 2025)
15. healthinsurance.org Alaska Medicaid
16. CMS Medicaid Indian Health Program Alaska
17. Alaska DOH Long-Term Medicaid Forecast FY2025-FY2045
18. Alaska DOH 2024 Annual Medicaid Reform Report
19. Tribal Health Reform Resource Center — Alaska Expansion
20. MACPAC — Medicaid’s Role in Health Care for American Indians and Alaska Natives
21. Alaska State Legislature
22. Alaska HB 346 (33rd Legislature) — gastric bypass coverage
23. CMS BALANCE Model
24. Alaska H.R. 1 AK Impacts (DOH)